KURA

5.89

4.54% -0.28

Handel nachbörslich: 5.94 0.05 +0.85%

Kura Oncology Inc (KURA)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$6.17

Offen:

$6.08

24-Stunden-Volumen:

1.45M

Relative Volume:

1.07

Marktkapitalisierung:

$478.88M

Einnahmen:

Nettoeinkommen (Verlust:

$-168.09M

KGV:

-2.7143

EPS:

-2.17

Netto-Cashflow:

$-138.01M

1W Leistung:

-16.45%

1M Leistung:

-19.65%

6M Leistung:

-67.35%

1J Leistung:

-71.07%

1-Tages-Spanne:

$5.82

$6.16

1-Wochen-Bereich:

$5.82

$6.95

52-Wochen-Spanne:

$5.82

$23.48

Kura Oncology Inc Stock (KURA) Company Profile

Firmenname

Kura Oncology Inc

Sektor

Healthcare (1172)

Branche

Biotechnology (673)

Telefon

(858) 500-8800

Adresse

12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA

Mitarbeiter

192

Twitter

@kuraoncology

Nächster Verdiensttermin

2025-02-21

Neueste SEC-Einreichungen

KURA's Discussions on Twitter

Vergleichen Sie KURA mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
KURA Kura Oncology Inc	5.89	478.88M	0	-168.09M	-138.01M	-2.17
VRTX Vertex Pharmaceuticals Inc	474.62	125.40B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	573.45	65.79B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	555.11	35.18B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	235.74	32.67B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	238.51	26.46B	3.81B	-644.79M	-669.77M	-6.24

Kura Oncology Inc Stock (KURA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-02-06	Herabstufung	BTIG Research	Buy → Neutral
2024-10-24	Eingeleitet	UBS	Buy
2024-10-14	Herabstufung	Stifel	Buy → Hold
2023-12-22	Eingeleitet	Mizuho	Buy
2023-08-11	Eingeleitet	BofA Securities	Buy
2023-07-27	Eingeleitet	Scotiabank	Sector Perform
2023-05-17	Eingeleitet	BTIG Research	Buy
2023-01-31	Eingeleitet	Stifel	Buy
2022-07-12	Eingeleitet	Cantor Fitzgerald	Overweight
2022-02-15	Eingeleitet	Jefferies	Buy
2021-05-05	Fortgesetzt	Credit Suisse	Outperform
2021-04-26	Fortgesetzt	Credit Suisse	Outperform
2020-12-07	Bestätigt	H.C. Wainwright	Buy
2020-12-03	Eingeleitet	Stifel	Buy
2020-11-05	Herabstufung	Piper Sandler	Overweight → Neutral
2020-07-07	Eingeleitet	Credit Suisse	Outperform
2020-05-05	Eingeleitet	Barclays	Overweight
2019-07-18	Eingeleitet	Deutsche Bank	Buy
2018-11-09	Eingeleitet	Piper Jaffray	Overweight
2018-08-01	Eingeleitet	H.C. Wainwright	Buy
2016-10-13	Fortgesetzt	Leerink Partners	Outperform
2016-01-22	Eingeleitet	JMP Securities	Mkt Outperform
2015-12-30	Eingeleitet	Oppenheimer	Outperform
2015-12-16	Eingeleitet	Citigroup	Buy

Alle ansehen

Kura Oncology Inc Aktie (KURA) Neueste Nachrichten

07:36 AM

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener

07:36 AM

07:33 AM

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

07:33 AM

07:30 AM

Kura Oncology Strengthens Team: Strategic Stock Options Awarded to New Hires - Stock Titan

07:30 AM

02:12 AM

Kura Oncology (NASDAQ:KURA) Upgraded to “Buy” at StockNews.com - Defense World

02:12 AM

Apr 03, 2025

Corient Private Wealth LLC Makes New $109,000 Investment in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World

Apr 03, 2025

Kura Oncology, Inc. (NASDAQ:KURA) Shares Bought by Teacher Retirement System of Texas - Defense World

Apr 03, 2025

Apr 01, 2025

Kura Oncology to Participate in Stifel Targeted Oncology Forum - The Manila Times

Apr 01, 2025

Kura Oncology CEO Set to Reveal Latest Cancer Treatment Strategy at Elite Stifel Forum - Stock Titan

Apr 01, 2025

Mar 31, 2025

Kura Oncology stock hits 52-week low at $6.75 amid market challenges - Investing.com

Mar 31, 2025

Virtu Financial LLC Makes New Investment in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World

Mar 31, 2025

Mar 28, 2025

Kura Oncology (NASDAQ:KURA) Shares Down 2.7%Should You Sell? - MarketBeat

Mar 28, 2025

Mar 27, 2025

Kura Oncology (NASDAQ:KURA) Upgraded by StockNews.com to Buy Rating - Defense World

Mar 27, 2025

Mar 26, 2025

Kura Oncology presents promising preclinical data By Investing.com - Investing.com South Africa

Mar 26, 2025

Kura Oncology presents promising preclinical data - Investing.com India

Mar 26, 2025

Kura Oncology Announces Preclinical Data for KO-2806 Selected for Oral Presentation at the 2025 AACR Annual Meeting - The Manila Times

Mar 26, 2025

Charles Schwab Investment Management Inc. Buys 10,542 Shares of Kura Oncology, Inc. (NASDAQ:KURA) - Defense World

Mar 26, 2025

Mar 25, 2025

Kura Oncology director Hasnain Faheem sells $181,456 in shares By Investing.com - Investing.com Australia

Mar 25, 2025

Mar 24, 2025

Insider Sell: Faheem Hasnain Sells 22,682 Shares of Kura Oncology Inc (KURA) - GuruFocus

Mar 24, 2025

Kura Oncology director Hasnain Faheem sells $181,456 in shares - Investing.com

Mar 24, 2025

Mar 23, 2025

Bank of New York Mellon Corp Decreases Stock Position in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World

Mar 23, 2025

Mar 22, 2025

Brokers Issue Forecasts for Kura Oncology FY2025 Earnings - Defense World

Mar 22, 2025

Mar 19, 2025

Kura Oncology (NASDAQ:KURA) Downgraded by StockNews.com to “Hold” - Defense World

Mar 19, 2025

Mar 16, 2025

US Bancorp DE Has $193,000 Stake in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World

Mar 16, 2025

Mar 15, 2025

Kura Oncology, Inc. (NASDAQ:KURA) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World

Mar 15, 2025

Mar 12, 2025

BTIG Research downgrades Kura Oncology Inc (KURA) stock to a Neutral - Knox Daily

Mar 12, 2025